Accuray Stock Analysis (NASDAQ:ARAY)

Add to My Stocks
$4.45 $0.15 (3.26%) ARAY stock closing price Jul 21, 2017 (Closing)
Watch Robo Advisor Video of ARAY Stock Analysis
Accuray
Updated on : Jul 21, 2017
previous close
ARAY 4.5 (0%)
S&P 500 2472.5 (0%)
Closing Price On: Jul 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical Instruments
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-0.9%
Operating Profit
Operating Margin:
-4.3%
Sector Average:
-0.5%
5 Quarter Net Profit
Net Margins
2017-Q3
%
LTM Margin
Debt/Equity Ratio
Debt:
94.2M
Debt/Equity Ratio:
 2.07
Compared to the industry
Cash Flow
Operating cash flow:
-$12.7M
Net Income:
-$5M
PROS      CONS
PS Valuation
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
ARAY PS :
1
Industry PS :
5.2
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-8.2%
Return on Equity:
-59%
Free Cash Flow Margin:
-13.5%
Double Tap To Exit Full Screen
0:00
/

Accuray Analysis Video

164 7 2

View Accuray stock analysis video. This is our ARAY analyst opinion covering the buy and sell arguments for ARAY stock.

Accuray Incorporated Stock Rating (1.8/5)

Our Accuray stock opinion is based on fundamentals of the company. This Accuray stock analysis is based on latest Q3 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy ARAY stock?

  • ARAY stock is trading at a favorable price to sales multiple of 1 as against the Medical Instruments industry average multiple of 5.2.

Should you sell ARAY stock?

  • Accuray sales shrank by -7.6% year-over-year in 2017 Q3.
  • Sales declined by -0.9% annually over the last 5 years.
  • Accuray reported an average operating margin of -4.3% over the Last Twelve Months (LTM).
  • Over the last 12 months, Accuray had an average Net loss of -8.6%.
  • With a debt/equity ratio of  2.07, Accuray is highly leveraged in comparison to Medical peers.
  • The company does not have profits. Hence the PE ratio is meaningless for ARAY stock.
  • Accuray has a negative ROIC (Return on Invested Capital) of -8.2%.
  • A negative ROE of -59% indicates that the company is not able to generate profits with the money shareholders have invested.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -13.5%.

Comments on this video and Accuray stock